vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and EXPRO GROUP HOLDINGS N.V. (XPRO). Click either name above to swap in a different company.
EXPRO GROUP HOLDINGS N.V. is the larger business by last-quarter revenue ($382.1M vs $284.0M, roughly 1.3× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 1.5%, a 94.8% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs -12.5%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs -0.2%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Expro is an energy services provider headquartered in Houston, Texas, United States.
ACAD vs XPRO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $382.1M |
| Net Profit | $273.6M | $5.8M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | 3.1% |
| Net Margin | 96.3% | 1.5% |
| Revenue YoY | 9.4% | -12.5% |
| Net Profit YoY | 90.3% | -74.9% |
| EPS (diluted) | $1.61 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $382.1M | ||
| Q3 25 | $278.6M | $411.4M | ||
| Q2 25 | $264.6M | $422.7M | ||
| Q1 25 | $244.3M | $390.9M | ||
| Q4 24 | $259.6M | $436.8M | ||
| Q3 24 | $250.4M | $422.8M | ||
| Q2 24 | $242.0M | $469.6M | ||
| Q1 24 | $205.8M | $383.5M |
| Q4 25 | $273.6M | $5.8M | ||
| Q3 25 | $71.8M | $14.0M | ||
| Q2 25 | $26.7M | $18.0M | ||
| Q1 25 | $19.0M | $13.9M | ||
| Q4 24 | $143.7M | $23.0M | ||
| Q3 24 | $32.8M | $16.3M | ||
| Q2 24 | $33.4M | $15.3M | ||
| Q1 24 | $16.6M | $-2.7M |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — | ||
| Q1 24 | 88.8% | — |
| Q4 25 | 6.1% | 3.1% | ||
| Q3 25 | 12.8% | 6.4% | ||
| Q2 25 | 12.2% | 7.7% | ||
| Q1 25 | 7.9% | 2.6% | ||
| Q4 24 | 59.1% | 7.3% | ||
| Q3 24 | 12.6% | 6.2% | ||
| Q2 24 | 12.6% | 5.9% | ||
| Q1 24 | 7.4% | 2.2% |
| Q4 25 | 96.3% | 1.5% | ||
| Q3 25 | 25.8% | 3.4% | ||
| Q2 25 | 10.1% | 4.3% | ||
| Q1 25 | 7.8% | 3.6% | ||
| Q4 24 | 55.4% | 5.3% | ||
| Q3 24 | 13.1% | 3.8% | ||
| Q2 24 | 13.8% | 3.3% | ||
| Q1 24 | 8.0% | -0.7% |
| Q4 25 | $1.61 | $0.05 | ||
| Q3 25 | $0.42 | $0.12 | ||
| Q2 25 | $0.16 | $0.16 | ||
| Q1 25 | $0.11 | $0.12 | ||
| Q4 24 | $0.86 | $0.20 | ||
| Q3 24 | $0.20 | $0.14 | ||
| Q2 24 | $0.20 | $0.13 | ||
| Q1 24 | $0.10 | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $196.1M |
| Total DebtLower is stronger | — | $79.1M |
| Stockholders' EquityBook value | $1.2B | $1.5B |
| Total Assets | $1.6B | $2.3B |
| Debt / EquityLower = less leverage | — | 0.05× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $196.1M | ||
| Q3 25 | $258.0M | $197.9M | ||
| Q2 25 | $253.6M | $206.8M | ||
| Q1 25 | $217.7M | $179.3M | ||
| Q4 24 | $319.6M | $183.0M | ||
| Q3 24 | $155.1M | $165.7M | ||
| Q2 24 | $177.1M | $133.5M | ||
| Q1 24 | $204.7M | $163.2M |
| Q4 25 | — | $79.1M | ||
| Q3 25 | — | $99.1M | ||
| Q2 25 | — | $121.1M | ||
| Q1 25 | — | $121.1M | ||
| Q4 24 | — | $121.1M | ||
| Q3 24 | — | $121.1M | ||
| Q2 24 | — | $121.1M | ||
| Q1 24 | — | $40.0M |
| Q4 25 | $1.2B | $1.5B | ||
| Q3 25 | $917.3M | $1.5B | ||
| Q2 25 | $822.4M | $1.5B | ||
| Q1 25 | $765.2M | $1.5B | ||
| Q4 24 | $732.8M | $1.5B | ||
| Q3 24 | $577.2M | $1.5B | ||
| Q2 24 | $516.7M | $1.5B | ||
| Q1 24 | $464.0M | $1.3B |
| Q4 25 | $1.6B | $2.3B | ||
| Q3 25 | $1.3B | $2.3B | ||
| Q2 25 | $1.2B | $2.3B | ||
| Q1 25 | $1.1B | $2.3B | ||
| Q4 24 | $1.2B | $2.3B | ||
| Q3 24 | $976.9M | $2.3B | ||
| Q2 24 | $914.1M | $2.3B | ||
| Q1 24 | $855.1M | $2.0B |
| Q4 25 | — | 0.05× | ||
| Q3 25 | — | 0.07× | ||
| Q2 25 | — | 0.08× | ||
| Q1 25 | — | 0.08× | ||
| Q4 24 | — | 0.08× | ||
| Q3 24 | — | 0.08× | ||
| Q2 24 | — | 0.08× | ||
| Q1 24 | — | 0.03× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $57.1M |
| Free Cash FlowOCF − Capex | — | $23.2M |
| FCF MarginFCF / Revenue | — | 6.1% |
| Capex IntensityCapex / Revenue | — | 8.9% |
| Cash ConversionOCF / Net Profit | -0.18× | 9.89× |
| TTM Free Cash FlowTrailing 4 quarters | — | $97.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $57.1M | ||
| Q3 25 | $74.3M | $63.2M | ||
| Q2 25 | $64.0M | $48.4M | ||
| Q1 25 | $20.3M | $41.5M | ||
| Q4 24 | $40.4M | $97.4M | ||
| Q3 24 | $63.2M | $55.3M | ||
| Q2 24 | $25.0M | $-13.2M | ||
| Q1 24 | $29.1M | $29.9M |
| Q4 25 | — | $23.2M | ||
| Q3 25 | $73.9M | $39.0M | ||
| Q2 25 | — | $27.2M | ||
| Q1 25 | — | $8.4M | ||
| Q4 24 | — | $53.0M | ||
| Q3 24 | $63.2M | $23.3M | ||
| Q2 24 | — | $-49.5M | ||
| Q1 24 | — | $-801.0K |
| Q4 25 | — | 6.1% | ||
| Q3 25 | 26.5% | 9.5% | ||
| Q2 25 | — | 6.4% | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | — | 12.1% | ||
| Q3 24 | 25.2% | 5.5% | ||
| Q2 24 | — | -10.5% | ||
| Q1 24 | — | -0.2% |
| Q4 25 | — | 8.9% | ||
| Q3 25 | 0.1% | 5.9% | ||
| Q2 25 | — | 5.0% | ||
| Q1 25 | — | 8.5% | ||
| Q4 24 | — | 10.2% | ||
| Q3 24 | 0.0% | 7.6% | ||
| Q2 24 | — | 7.7% | ||
| Q1 24 | — | 8.0% |
| Q4 25 | -0.18× | 9.89× | ||
| Q3 25 | 1.03× | 4.52× | ||
| Q2 25 | 2.40× | 2.69× | ||
| Q1 25 | 1.07× | 2.98× | ||
| Q4 24 | 0.28× | 4.23× | ||
| Q3 24 | 1.93× | 3.40× | ||
| Q2 24 | 0.75× | -0.86× | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
XPRO
| NLA | $130.3M | 34% |
| ESSA | $116.3M | 30% |
| MENA | $93.0M | 24% |
| Other | $42.5M | 11% |
